Newswire (Published: Thursday, December 13, 2018, 4:01:00 PM CST, Received: Thursday, December 13, 2018, 5:45:54 PM CST)
Word Count: 472
By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Enzymes and Coenzymes - Prostate-Specific Antigen. According to news originating from Tokyo, Japan, by NewsRx correspondents, research stated, "To identify patients at extremely low risk of biochemical recurrence (BCR) of prostate cancer after low-dose-rate brachytherapy (LDR-BT) to determine when prostate-specific antigen (PSA) monitoring can be stopped. We retrospectively reviewed clinicopathologic data of patients with prostate cancer who underwent LDR-BT between 2003 and 2011."
Our news journalists obtained a quote from the research from the Department of Urology, "Of 1569 patients reviewed, 689 (43.9%) received combination external beam radiotherapy, and 970 (61.8%) had neoadjuvant hormonal therapy. We stratified patients according to risk factors identified by multivariate analysis and assessed the factors for an association with BCR (defined as >= 2 ng/mL higher than the nadir). The median followup was 96 months. Of 1531 patients who were BCR-free at 3 years after treatment, 76 subsequently developed BCR; of 1500 who were BCR-free at 5 years, 45 eventually had BCR. On multivariate analysis, independent risk factors for BCR were the National Comprehensive Cancer Network risk group at diagnosis and PSA levels at 3 or 5 years after radio-therapy. In the low-risk group, no patient with a PSA level <= 0.2 ng/mL at 3 years after radiotherapy subsequently developed BCR. In the intermediate-risk group, no patients with a PSA level <= 0.2 ng/mL at 5 years subsequently developed BCR. The National Comprehensive Cancer Network risk group at diagnosis and PSA values at 3 and 5 years after LDR-BT are independently associated with a risk of later BCR."
According to the news editors, the research concluded: "Using these two factors may help to select patients for whom PSA monitoring could be stopped because they have an extremely low risk of later BCR."
For more information on this research see: Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy. Brachytherapy, 2018;17(6):899-905. Brachytherapy can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Brachytherapy - www.journals.elsevier.com/brachytherapy/)
The news correspondents report that additional information may be obtained from N. Niwa, Tokyo Saiseikai Cent Hosp, Dept. of Urol, Tokyo, Japan. Additional authors for this research include K. Matsumoto, T. Nishiyama, Y. Yagi, C. Ozu, K. Nakamura, S. Saito and M. Oya (see also Enzymes and Coenzymes - Prostate-Specific Antigen).
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.brachy.2018.08.018. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
New York City
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Treatments and Therapies